Artificial Intelligence: US FDA Plans Guidances On Algorithm Bias, Product Development

Cross-center AI strategy features collaboration between drug, biologic, device and combination product staff to ensure regulatory predictability. ‘Assurance labs’ offering independent valuation of models should be available by year-end as part of FDA’s involvement with Coalition for Health AI.

artificial intelligence
• Source: Shutterstock

Identifying and fighting bias in artificial intelligence will be one of many priorities for the US Food and Drug Administration going forward as it enhances its regulatory capacity for the technology.

The FDA’s drug, biologic, and device centers, as well as its Office of Combination Products, will collaborate to ensure regulatory certainty and allow for innovation with AI. In a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Digital Technologies

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

Bayer Study Shows Potential Of Saliva-Based Biomarker For Healthy Aging

 
• By 

Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”

Church & Dwight Launching Sugar-Free Vitafusion, Looks To AI As Sweet Spot For All Growth

 

AI prowess “will not be a competitive advantage long-term. It's going to be table stakes. But there are people who are going to get there sooner and they will have an advantage for a while,” says C&D CEO Matthew Farrell. P&G’s investment in AI, meanwhile, produced its “Great Idea Generator proprietary platform.”

EU Industry Calls For Earlier And Harmonized Adoption Of Electronic Product Information

 
• By 

Electronic product information should be “fully operational” within four years after the entry into force of the revised EU pharma legislation and should precede the phasing out of paper leaflets, proposes the Inter-Association Taskforce (IATF) on ePI. Once the new system is up and running, ePI should be implemented across the EU in a harmonized way, with all EU member states adopting the same standard, it says.

More from HBW Insight

Galenica’s Verfora Gets Off To Flying Start In Swiss CHC Market

 
• By 

Verfora grows almost 10-times faster than the Swiss consumer health market in the opening months of 2025.

Review Suggests Advantage Of Bayer’s Iberogast Advance For Digestive Disorders

 
• By 

Bayer's Iberogast Advance's combination of six herbal ingredients may produce a synergistic effect that acts on multiple underlying issues contributing to digestive disorders like functional dyspepsia (FD) and irritable bowel syndrome (IBS), a recently published study suggests.

E.l.f. Plans To Acquire Hailey Bieber Beauty Brand For $1Bn

 

E.l.f. Beauty, Inc. has agreed to acquire celebrity and model Hailey Bieber’s rhode lifestyle beauty brand for $1bn, the firm reported during a 28 May fiscal fourth quarter earnings call, during which it also announced plans to raise product prices to ‘partially’ mitigate the impact of tariffs.